Skip to main content
Premium Trial:

Request an Annual Quote

Danaher to Ship First Next-Gen Sequencer This Week

NEW YORK (GenomeWeb News) – Danaher Motion – Dover, a branch of US technology conglomerate Danaher that has been developing a low-cost open-source next-generation sequencer with George Church’s group at Harvard Medical School, is scheduled to ship the first commercial version of the tool later this week to the Church lab, GenomeWeb Daily News sister publication In Sequence reported yesterday.
 
In addition, the Broad Institute said it will order at least one of the instruments in order to evaluate the technology, according to the company.
 
Danaher has already received other orders and order commitments for the instrument, including an order from the Max Planck Institute of Molecular Genetics in Berlin, and plans to showcase the instrument in a hotel suite at the Advances in Genome Biology and Technology meeting on Marco Island this week.
 
The company said it will market the instrument, called the Polonator G.007, with reagent kits, flow cells, user support, and protocols and software developed by the Church lab.
 
The system currently supports paired-end sequencing with read lengths of two times 14 bases. Performance metrics such as accuracy and throughput will be available within a month, according to the Church lab.
 
According to marketing literature, the Danaher-Church team has “identified the upfront and recurring cost of second-generation sequencing as key factors inhibiting the rate of adoption, and have assiduously sought to drive these as low as possible.”
 
The instrument’s list price, $150,000, is indeed lower than those of other available next-generation sequencers — sold by Applied Biosystems, Illumina, and Roche’s 454 Life Sciences subsidiary — which list for between $430,000 and almost $600,000.
 
Researchers in the Church lab are still determining the performance of the instrument, including its throughput and accuracy, and “expect those figures within the next month,” Greg Porreca, a developer in the Church group, told In Sequence by e-mail this week.
 

 
A comprehensive version of this article appears in this week's issue of In Sequence.

The Scan

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.